Shopping Cart
Remove All
Your shopping cart is currently empty
Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $415 | - | In Stock | |
| 5 mg | $1,230 | - | In Stock | |
| 10 mg | $1,990 | - | In Stock |
| Description | Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, capable of inhibiting the growth of xenograft tumours expressing mutant EGFR vIII and wild-type EGFR. It can be conjugated with the ADC molecule Depatuxizumab mafodotin for the study of glioblastoma (GBM) and head and neck squamous cell carcinoma (SCCHN). |
| In vivo | Depatuxizumab (10, 40 mg/kg, intraperitoneal injection, 3 times a week for 2 weeks) can significantly inhibit tumor growth in the U87MGde2-7 glioblastoma multiforme (GBM) model and A431 squamous cell carcinoma model of Nu/Nu mice. Depatuxizumab (10, 40 mg/kg, intraperitoneal injection, 3 times a week for 2 weeks) can inhibit tumor growth and pEGFR levels in the EGFRvIII-positive GBM-SN0199-PDX model of NSG mice. [1] |
| Synonyms | ABT-806, ABT806 |
| Cas No. | 1471999-69-5 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.